Welcome to our dedicated page for Hutchmed (China) news (Ticker: HCM), a resource for investors and traders seeking the latest updates and insights on Hutchmed (China) stock.
HUTCHMED (China) Limited (HCM) news covers the company’s ongoing work as a commercial-stage biopharmaceutical developer of targeted therapies and immunotherapies for cancer and immunological diseases. Press releases frequently describe progress across its in-house pipeline, regulatory milestones in China and abroad, and updates on marketed medicines such as ELUNATE® (fruquintinib), ORPATHYS® (savolitinib) and SULANDA® (surufatinib).
Investors and healthcare professionals following HUTCHMED news can expect detailed reports on clinical trial results, including Phase II and Phase III data in solid tumors and autoimmune hematologic diseases. Recent announcements have highlighted Phase III outcomes for savolitinib plus TAGRISSO® in EGFR-mutated non-small cell lung cancer, topline Phase III results for sovleplenib in warm antibody autoimmune hemolytic anemia, and initiation or expansion of studies such as the Phase II/III trial of surufatinib and camrelizumab in metastatic pancreatic ductal adenocarcinoma.
News items also address regulatory and reimbursement developments, such as New Drug Application acceptances with priority review for savolitinib in MET-amplified gastric cancer and fanregratinib in intrahepatic cholangiocarcinoma, as well as inclusion of HUTCHMED-associated medicines on China’s National Reimbursement Drug List and the National Commercial Health Insurance Innovative Drug List. These updates provide context on how the company’s therapies may reach broader patient populations.
Another recurring theme is platform and pipeline strategy, including announcements about the ATTC (Antibody-Targeted Therapy Conjugate) platform and first-in-human trials of HMPL-A251, as well as presentations at major scientific meetings such as ESMO, ASH and AACR-NCI-EORTC. For those tracking HCM, this news feed offers a centralized view of clinical data readouts, partnership activities, regulatory interactions and broader R&D progress. Bookmarking this page allows readers to follow how HUTCHMED’s oncology and immunology programs evolve over time.
HUTCHMED (Nasdaq/AIM: HCM) presented preclinical data for HMPL-A251 at the AACR-NCI-EORTC conference (Oct 22–26, 2025). HMPL-A251 is an ATTC combining a humanized anti-HER2 IgG1 with a highly potent, selective PI3K/PIKK inhibitor payload via a cleavable hydrophilic linker. In vitro it showed broad activity across 130 tumor cell lines, HER2-dependent killing and a bystander effect. In vivo a single IV dose induced tumor regression across HER2-positive and HER2-low models, with efficacy comparable or superior to T-DXd in most models. Free payload plasma exposure was very low (mass ratio <1:500,000). Global clinical trials are planned around end of 2025 with additional IND filings in 2026.
HUTCHMED (Nasdaq/AIM: HCM, HKEX: 13) appointed Professor Tan Shao Weng, Daniel as an Independent Non-executive Director and member of its Technical Committee effective 15 October 2025.
Professor Tan, age 47, brings >20 years in oncology, leads the NCCS Experimental Cancer Therapeutics Unit (running ~30–40 Phase I trials), and is principal investigator on an NMRC Lung Cancer grant (2025–2029). His annual director fees are US$76,000 plus US$8,000 for committee membership. The appointment term runs to the next AGM and then on successive 12‑month terms, subject to re‑election and company articles.
HUTCHMED (Nasdaq/AIM: HCM) reported Phase III FRUSICA-2 results for the fruquintinib plus sintilimab combination in second-line advanced renal cell carcinoma, to be presented at ESMO on Oct 17, 2025.
Key outcomes at PFS cutoff Feb 17, 2025: median PFS 22.2 months vs 6.9 months (HR 0.373, p<0.0001); ORR 60.5% vs 24.3% (OR 4.622, p<0.0001); median DoR 23.7 vs 11.3 months. Overall survival data remain immature (~20% mature). The safety profile was tolerable with grade ≥3 TEAEs 71.4% vs 58.8%. An NDA has been accepted by China NMPA for review.
HUTCHMED (NASDAQ/AIM:HCM) has announced multiple data presentations at the upcoming ESMO Congress 2025 in Berlin, Germany. The highlight will be the presentation of results from the FRUSICA-2 registration study examining fruquintinib and sintilimab combination as second-line treatment for renal cell carcinoma in a Mini Oral session.
Additional presentations include analyses of the FRUSICA-1 study in endometrial cancer and the SAVANNAH and SACHI studies in non-small cell lung cancer. The congress will feature both company-sponsored and investigator-initiated studies across multiple cancer types, including colorectal, gastric, lung, and pancreatic cancers, showcasing HUTCHMED's expanding oncology portfolio.
HUTCHMED (NASDAQ/AIM/HKEX:HCM) has announced an upcoming Research & Development update event scheduled for October 31, 2025. The presentation will feature Dr. Michael Shi, Executive Vice President, Head of R&D and Chief Medical Officer, who will discuss the company's R&D strategy and vision.
The event will highlight HUTCHMED's Antibody Targeted Therapy Conjugates platform, including updates on their lead candidate HMPL-A251 and late-stage pipeline developments. The presentation will be held in-person in Shanghai from 3:00-5:00 p.m. HKT in Chinese, with a concurrent webcast. An English webcast will follow at 8:00 p.m. HKT/8:00 a.m. EDT.
HUTCHMED (Nasdaq/AIM:HCM) announced upcoming presentations of clinical data at two major conferences: the 2025 World Conference on Lung Cancer (WCLC) in Barcelona and the CSCO Annual Meeting 2025 in Jinan, China.
At WCLC, key presentations will focus on savolitinib, their MET tyrosine kinase inhibitor being developed with AstraZeneca, including updates from the SACHI and SAVANNAH trials in non-small cell lung cancer patients. At CSCO, HUTCHMED will present first-time data for HMPL-653, their novel CSF-1R inhibitor, from a Phase I study in tenosynovial giant cell tumor patients.
Additional presentations will cover multiple studies of fruquintinib and surufatinib across various cancer types, including colorectal, pancreatic, and neuroendocrine tumors, often in combination with other therapies.
HUTCHMED (NASDAQ/AIM:HCM) announced that CEO Dr Weiguo Su will take a leave of absence due to health reasons. The company has appointed Johnny Cheng, the current Chief Financial Officer, as Acting CEO with immediate effect, while maintaining his CFO responsibilities.
Chairman Dr Dan Eldar expressed full support for Dr Su and confidence in Mr Cheng's leadership capabilities. The Board assured that all research, development, and commercial initiatives will remain on track during this transition period. Dr Su emphasized that this was a difficult decision and expressed confidence in the team's ability to execute the company's strategy.
HUTCHMED (NASDAQ:HCM) has completed patient enrollment for the SANOVO Phase III trial, evaluating the combination of ORPATHYS® (savolitinib) and TAGRISSO® (osimertinib) as a first-line treatment for non-small cell lung cancer (NSCLC) patients with EGFR mutation and MET overexpression in China.
The randomized, controlled study will compare the efficacy and safety of the combination therapy versus TAGRISSO® alone. The trial's primary endpoint is progression-free survival (PFS), with secondary endpoints including overall survival, objective response rate, and safety measures. Topline results are expected in the second half of 2026, potentially leading to a supplementary New Drug Application to China's NMPA.
HUTCHMED (NASDAQ/AIM:HCM) reported significant financial and operational achievements in H1 2025. The company achieved $455.0 million in net income (vs $25.8M in H1 2024), largely driven by a $416.3 million divestment gain from a non-core joint venture. Total revenue was $277.7 million, down 9% year-over-year.
Key highlights include ORPATHYS® securing China approval for its third lung cancer indication, triggering an $11.0 million milestone payment from AstraZeneca. FRUZAQLA® sales by Takeda grew 25% to $162.8 million, expanding to over 30 countries. The company's cash balance stood at $1.36 billion as of June 30, 2025.
HUTCHMED also announced progress with its new Antibody-Targeted Therapy Conjugates (ATTC) platform, with clinical development planned for late 2025. The company presented positive results from multiple clinical trials, including the SACHI and SAVANNAH lung cancer trials.
HUTCHMED (NASDAQ/AIM/HKEX: HCM) has scheduled the announcement of its 2025 half-year financial results for Thursday, August 7, 2025 at 7:00 am EDT. The company will host two separate webcasts for analysts and investors:
The English presentation will take place on August 7, 2025, at 8:00 am EDT, while the Chinese (Putonghua) presentation will be held on August 8, 2025, at 8:30 am HKT. Both webcasts will be accessible through the company's website, with presentation materials available for download before the events and replays available afterward.
FAQ
What is the current stock price of Hutchmed (China) (HCM)?
What is the market cap of Hutchmed (China) (HCM)?
